Insamo
Chippendale, AU · 7 known investors
Insamo develops an automated platform for drug discovery that designs, synthesizes, and tests cyclic peptides at scale using machine learning and proprietary experimental data. The company targets the development of treatments for challenging diseases through membrane-permeable and orally available compounds.
AI & Machine LearningBiotechDeep Tech
Founders & leadership
TC
Tim CravenCEO
TP
Toby PassiouraCSO
GM
Glen McIntyreCOO
CG
COREY GOODMANDirector
TC
TIMOTHY CRAVENExecutive Officer, Director
MH
MATT HERSHENSONDirector
TP
TOBY PASSIOURAExecutive Officer, Director
GM
GLEN MCINTYREExecutive Officer, Director
Investors · 7
Reported raises · per SEC filings
Form D private placements▶$2.3MraisedDec 2023 · 2 investors · BiotechnologyRule 506(b)
▶$2.3MraisedDec 2023 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- COREY GOODMANDirector
- TOBY PASSIOURAExecutive Officer, Director
- MATT HERSHENSONDirector
- GLEN MCINTYREExecutive Officer, Director
- TIMOTHY CRAVENExecutive Officer, Director
- Offering amount
- $2.3M
- Amount sold
- $2.3M
- First sale
- Dec 2023
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
▶$9.5MraisedMar 2023 · 4 investors · BiotechnologyRule 506(b)
▶$9.5MraisedMar 2023 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- COREY GOODMANDirector
- TIMOTHY CRAVENExecutive Officer, Director
- MATT HERSHENSONDirector
- TOBY PASSIOURAExecutive Officer, Director
- GLEN MCINTYREExecutive Officer, Director
- Offering amount
- $10M
- Amount sold
- $9.5M
- First sale
- Mar 2023
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.